Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA To Follow EMEA's Lead: ODAC Votes To Require Randomized Controlled Trials For Future Cutaneous T-Cell Lymphoma Drug Approval

Executive Summary

FDA may soon follow the European Medicine Agency's lead in approval standards for cutaneous T-cell lymphoma drugs by requiring randomized clinical trials for future drug development
Advertisement

Related Content

Buoyed by Positive Trial Data, Private Yaupon Prepares To File Topical Chemo For Early CTCL
Post-Market Trials Could Broaden Label For Allos' Newly Approved Folotyn
Post-Market Trials Could Broaden Label For Allos' Newly Approved Folotyn
Post-Market Requirements Could Broaden Label For Allos' Newly Approved PTCL Drug Folotyn
ODAC Backs Allos' Folotyn Despite Fickle Data, Finds Many Paths Forward
ODAC Backs Allos' Folotyn Despite Fickle Data, Finds Many Paths Forward
Continued Genzyme Problems Offer Gaucher Opportunity To Competitors

Topics

Advertisement
UsernamePublicRestriction

Register

PS051452

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel